Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG KWIKPEN versus MERILOG SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG KWIKPEN versus MERILOG SOLOSTAR.
HUMALOG KWIKPEN vs MERILOG SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Subcutaneous injection: individualize dose; typical total daily dose 0.5-1 unit/kg; rapid-acting insulin given 0-15 minutes before or immediately after meals.
0.5 mg subcutaneously once a day.
None Documented
None Documented
Terminal elimination half-life: approximately 26 minutes (range 0.6-1.2 hours in some studies) following subcutaneous administration, reflecting rapid clearance from the systemic circulation.
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Renal: 60-80% of insulin lispro is metabolized primarily in the liver and kidneys, with metabolites and a small amount of intact drug excreted in urine.
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Category C
Category C
Insulin
Insulin